About US
Contact us
-
Neovacs and 3P Biopharmaceuticals partner to manufacture IFNaFrench company Neovacs and Spanish-based 3P Biopharmaceuticals have collaborated to manufacture interferon alpha (IFNα). The partnership follows the recent acquisition of the technology for the manuf2016/11/28
-
M&As this week: Sun Pharmaceuticals, AllerganSun Pharmaceuticals Industriesplans to acquire an 85.1% stake in JSC Biosintez for a purchase consideration of $60m. The acquisition will enable Sun Pharmaceuticals to gain local manufacturing capa2016/11/28
-
Pharma already balks at Germany's tough pricing regime--and it could get even tougherGermany may stiffen up its already strict drug pricing rules, a move that could exacerbate the pharma industry’s sometimes-acrimonious relationship with health officials there. Under a proposal now u2016/11/25
-
Brexit battle heats up over winning EMA from LondonA long list of EU countries would love to behometo the European Medicines Agency (EMA) post-Brexit--France, Italy, Denmark, Sweden, Hungary and more. But the U.K. is not going to let it go without put2016/11/25
-
FDA nod helps BMS' Opdivo even the head-and-neck cancer score with Merck's KeytrudaThursday was quite the day for Bristol-Myers Squibb’s Opdivo. After becoming the first med to succeed in a Phase III gastric cancer trial, the drug nabbed anFDA approvalin head-and-neck cancer--and ev2016/11/24
-
UPDATED: Gilead snags FDA approval for improved hep B drug VemlidyGilead Sciences, whose hepatitis C dynasty has been slipping, haswon approvalfor its next-gen hepatitis B treatment. The Foster City, CA-based drugmaker said Thursday that the FDA had approvedVemlidy2016/11/24
-
GSK files regulatory submission with US FDA for FF / UMEC / VI therapyGlaxoSmithKline (GSK) and Innoviva have filed a regulatory submission with the US Food and Drug Administration (FDA) for fluticasone furoate / umeclidinium / vilanterol (FF / UMEC / VI 100mcg / 62.5mc2016/11/23
-
Novartis acquires Selexys Pharmaceuticals in US for $665mNovartis has acquired US-based hematologic and inflammatory disorder theraputics developer Selexys Pharmaceuticals in a deal valued at approximately $665m. The company exercised its acquisition right2016/11/23
-
Russian Federation set to introduce new scientific drug research projectsThe Russian Federation’s Industry and Trade Ministry is set to introduce the latest scientific research on drugs, with an aim to help innovative developments enter Russia and western markets. As part2016/11/22
-
AstraZeneca’s MedImmune completes licensing agreement with Allergan for MEDI2070British drugmaker AstraZeneca’s global biologics research and development arm MedImmune has completed a licensing agreement with Allergan for the global rights to IL-23 monoclonal antibody MEDI2070.2016/11/22